Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chest x-ray

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    552 result(s) found for: Chest x-ray. Displaying page 1 of 28.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-000982-51 Sponsor Protocol Number: P05336 Start Date*: 2009-07-01
    Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation
    Full Title: Infliximab as First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial
    Medical condition: Moderate-to-severe active axial spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058338 Spondylarthritis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed) AT (Completed) BE (Completed) DE (Completed) HU (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-002475-29 Sponsor Protocol Number: GS-US-218-1502 Start Date*: 2015-02-10
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT...
    Medical condition: Respiratory Syncytial Virus (RSV) Infection of the lower respiratory tract.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10039247 RSV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001126-21 Sponsor Protocol Number: 100423 Start Date*: 2021-04-14
    Sponsor Name:Division of Thoracic and Hyperbaric Surgery, Medical University Graz
    Full Title: Hyperbaric Oxygenation for patients with post-COVID-19 sequelae. Pilot study.
    Medical condition: Multiorgan symptoms after COVID-19 infection (Long COVID)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002320-34 Sponsor Protocol Number: M01 Start Date*: 2005-10-12
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Randomized controlled 12 months trial with etanercept (enbrel ®) vs. sulfasalazine followed by an open-label extension with etanercept up to week 540 in early axial spondyloarthritis with focus on ...
    Medical condition: The proposed study is designed to get first data on efficacy and safety of etanercept in the treatment of patients with moderate to severe early axial Spondyloarthritis (SpA) with disease duration...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003542-32 Sponsor Protocol Number: SCOPE Start Date*: 2020-02-28
    Sponsor Name:Dr. José Manuel Porcel Pérez
    Full Title: Randomised clinical trial: saline washouts versus standard treatment in complicated parapneumonic pleural effusion or empyema. SCOPE study.
    Medical condition: Treatment of complicated parapneumatic pleural effusion or empyema
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001343-55 Sponsor Protocol Number: A6061030 Start Date*: 2006-08-02
    Sponsor Name:Pfizer, S.A.
    Full Title: A PHASE 2B LONG-TERM, RANDOMIZED, OPEN-LABEL, SAFETY AND TOLERABILITY TRIAL COMPARING [S,S]-REBOXETINE (PNU-165442G) WITH ROUTINE CARE IN PATIENTS WITH POSTHERPETIC NEURALGIA (PHN).
    Medical condition: Postherpetic neuralgia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029223 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Prematurely Ended) GB (Completed) LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002482-34 Sponsor Protocol Number: GAM10-10 Start Date*: 2020-05-21
    Sponsor Name:Octapharma USA
    Full Title: Efficacy and safety of Octagam 10% therapy in COVID-19 patients with severe disease progression
    Medical condition: COVID-19
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-005750-27 Sponsor Protocol Number: MT-1303-E06 Start Date*: 2013-08-16
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC)
    Full Title: A Phase IIa, Multicentre, Randomised, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate Safety, Tolerability and Clinical Efficacy of MT-1303 in Subjects with Moderate to Severe Ch...
    Medical condition: Moderate to Severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) EE (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-001622-64 Sponsor Protocol Number: TAC-COVID19 Start Date*: 2020-04-19
    Sponsor Name:Dra Ana Pueyo Bastida
    Full Title: OUTPATIENT TREATMENT OF COVID-19 WITH EARLY PULMONARY CORTICOSTEROIDS AS AN OPPORTUNITY TO MODIFY THE COURSE OF THE DISEASE
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002474-36 Sponsor Protocol Number: GS-US-218-0108 Start Date*: 2014-11-24
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT...
    Medical condition: Respiratory Syncytial Virus (RSV) Infection of the upper respiratory tract.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10039247 RSV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) GB (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-001744-11 Sponsor Protocol Number: PT003019-01 Start Date*: 2016-10-31
    Sponsor Name:Pearl Therapeutics, Inc.
    Full Title: A Randomized, Double-Blind, Two Treatment, Two Period, Chronic Dosing (2 Weeks), Cross-Over, Multi-Center Study to Evaluate the Effects of PT001 and PT005 on Specific Image Based Airway Volumes and...
    Medical condition: Moderate to severe Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000015472 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001743-36 Sponsor Protocol Number: PT003018-00 Start Date*: 2015-12-01
    Sponsor Name:Pearl Therapeutics, Inc.
    Full Title: A Randomized, Double-Blind, Two Treatment, Two Period, Chronic Dosing (2 Weeks), Cross-Over, Single-Center Study to Evaluate the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volu...
    Medical condition: Moderate to severe Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004655-75 Sponsor Protocol Number: D5970C00002 Start Date*: 2017-07-18
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Glycopyrronium/Formoterol Fumarate fixed-dose combination relative to Umeclidinium/V...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-000729-70 Sponsor Protocol Number: MKI106209 Start Date*: 2006-07-11
    Sponsor Name:GlaxoSmithKline Research and Development
    Full Title: A randomised, double-blind, placebo-controlled parallel study to assess the safety, tolerability, pharmacodynamics and steady-state pharmacokinetics of repeated doses of GW856553 in patients with C...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001307-11 Sponsor Protocol Number: A6061031 Start Date*: 2006-10-02
    Sponsor Name:Pfizer Ltd
    Full Title: A PHASE 2B LONG-TERM, RANDOMIZED, OPEN-LABEL, SAFETY AND TOLERABILITY TRIAL COMPARING [S,S]-REBOXETINE (PNU-165442G) WITH ROUTINE CARE IN PATIENTS WITH CHRONIC PAINFUL DIABETIC PERIPHERAL NEUROPATH...
    Medical condition: Diabetic Peripheral Neuropathy
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012683 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) EE (Prematurely Ended) FI (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003439-53 Sponsor Protocol Number: TMC353121-TiDP19-C202 Start Date*: 2006-12-08
    Sponsor Name:Tibotec Pharmaceuticals Ltd
    Full Title: A double blind, randomized, placebo-controlled study to evaluate the antiviral activity, safety and plasma pharmacokinetics of multiple intravenous doses of TMC353121 in hematopoietic stem cell tra...
    Medical condition: Respiratory Synctycial Virus (RSV)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001820-36 Sponsor Protocol Number: 114886 Start Date*: 2012-10-15
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II observer blind, randomised, controlled study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ candidate tuberculosis vaccine GSK 692342 when administered to ...
    Medical condition: Vaccination against tuberculosis (TB) in adults aged 18 to 59 years with TB disease.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004865 10045023 Tuberculosis prophylaxis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004617-42 Sponsor Protocol Number: ICA-17043-10 Start Date*: 2005-06-22
    Sponsor Name:Icagen Inc
    Full Title: A Phase III, Multicenter, 52-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Efficacy and Safety of ICA-17043 with or without Hydroxyurea Therapy in Patients with Sickle Ce...
    Medical condition: Sickle Cell Disease
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-001023-14 Sponsor Protocol Number: SG016 Start Date*: 2020-03-17
    Sponsor Name:Synairgen Research Limited
    Full Title: A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFNβ-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infectio...
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10051905 Coronavirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-000580-24 Sponsor Protocol Number: Start Date*: 2019-05-17
    Sponsor Name:Hull & East Yorkshire Hospitals NHS trust
    Full Title: A single arm, open-label clinical trial of azithromycin in pulmonary sarcoidosis
    Medical condition: Sarcoidosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 12 20:50:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA